Abstracts tagged "small molecules"

Abstract Number: 314 • 2019 ACR/ARP Annual Meeting
Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data
Jing Li ¹, Julia Kay ¹, Jinoos Yazdany ¹ and Gabriela Schmajuk², ¹UCSF Division of Rheumatology, San Francisco, CA, ²UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) is recommended for patients initiating biologics or new synthetic DMARDs, which can increase the risk…
Abstract Number: 2059 • 2018 ACR/ARHP Annual Meeting
Inhibition of the Transcription Factor That Drives IL-17 Expression Suppresses Inflammation, Joint Damage, and New Bone Formation in Experimental Spondyloarthritis in HLA-B27 Transgenic Rats
Joel Taurog¹, Jiankun Zhu¹, Michael Kort², Shaughn Bryant³, Lucy Phillips³ and Wendy Waegell³, ¹Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie, Inc., North Chicago, IL, ³AbbVie, Inc., Worcester, MA
Background/Purpose: The IL-17 axis has been identified as a central pathway in SpA pathogenesis. Targeting this axis in AS and PsA significantly suppresses inflammation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].